Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial

Papandreou, Christopher; Bulló, Mònica; Tinahones Madueño, Francisco José; Martínez-González, Miguel Ángel, 1957-; Corella, Dolores; Fragkiadakis, Georgios A.; López-Miranda, José; Estruch, Ramón; Fitó Colomer, Montserrat; Salas-Salvadó, Jordi

Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Papandreou, Christopherca
dc.contributor.author Bulló, Mònicaca
dc.contributor.author Tinahones Madueño, Francisco Joséca
dc.contributor.author Martínez-González, Miguel Ángel, 1957-ca
dc.contributor.author Corella, Doloresca
dc.contributor.author Fragkiadakis, Georgios A.ca
dc.contributor.author López-Miranda, Joséca
dc.contributor.author Estruch, Ramónca
dc.contributor.author Fitó Colomer, Montserratca
dc.contributor.author Salas-Salvadó, Jordica
dc.date.accessioned 2018-07-06T06:56:33Z
dc.date.available 2018-07-06T06:56:33Z
dc.date.issued 2017
dc.description.abstract BACKGROUND: Limited prospective studies have examined changes in non-alcoholic fatty-liver disease (NAFLD) related serum-metabolites and none the effects of NAFLD-reversion. We aimed to evaluate whether perturbations in metabolites indicate predisposition to NAFLD development and to assess the effects of NAFLD reversion on metabolite profiles. METHODS: A targeted liquid-chromatography tandem mass-spectrometry metabolic profiling (n = 453 metabolites) approach was applied, using serum from 45 subjects of the PREDIMED study, at baseline and after a median 3.8-year follow-up. NAFLD was determined using the hepatic steatosis index; with three groups classified and studied: Group 1, not characterized as NAFLD cases during the follow-up (n = 15); Group 2, characterized as NAFLD during the follow-up (n = 15); Group 3, characterized as NAFLD-reversion during the follow-up (n = 15). RESULTS: At baseline, significantly lower storage and transport lipids (triacylglycerols and cholesteryl esters), several monoetherglycerophosphocholines, acylglycerophosphocholines, ceramides and ceramide to sphingomyelin ratio (P < 0.05), were found; whereas a higher L-cystine to L-glutamate ratio (P < 0.05) was observed, in group 2 as compared to group 1.P-ether acylglycerophosphocholines, ceramides and sphingolipids were significantly different betweengroup 3 and group 1 (P < 0.05). Higher 16:1n-7 to 16:0, and 18:0 to16:0 ratio (P < 0.05), while lower 18:1n-9 to 18:0, 16:0 to 18:2n-6, and 18:3n-6 to 18:2n-6 ratio (P < 0.05) were observed in the final, compared to baseline values, in groups 2 and 3. CONCLUSION: The rearrangement of lipid biosynthesis and serum transport may indicate predisposition to NAFLD development. Despite an expected reduction of hepatic lipotoxicity and improved hepatic function in the participants of the study characterized as NAFLD-reversing, the side effects of NAFLD in serum metabolic profiles remained present.
dc.format.mimetype application/pdf
dc.identifier.citation Papandreou C, Bullò M, Tinahones FJ, Martínez-González MÁ, Corella D, Fragkiadakis GA. Et al. Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial. Nutr Metab (Lond). 2017 Sep 2;14:58. DOI: 10.1186/s12986-017-0213-3
dc.identifier.doi http://dx.doi.org/10.1186/s12986-017-0213-3
dc.identifier.issn 1743-7075
dc.identifier.uri http://hdl.handle.net/10230/35041
dc.language.iso eng
dc.publisher BioMed Centralca
dc.relation.ispartof Nutrition & Metabolism. 2017 Sep 2;14:58
dc.rights Copyright © The Author(s). 2017. Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.subject.keyword Fatty acid metabolism
dc.subject.keyword Hepatic lipotoxicity
dc.subject.keyword Metabolomics
dc.subject.keyword Non-alcoholic fatty liver disease
dc.subject.other Fetge--Malalties
dc.subject.other
dc.title Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trialca
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)